Binds A Virus Or Component Or Product Thereof (e.g., Virus Associated Antigen, Etc.) Patents (Class 435/339)
-
Patent number: 8574581Abstract: Monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes or neuraminidase glycoprotein of N1 subtypes of avian influenza virus (AIV) are provided. The monoclonal antibodies and related binding proteins are useful for the detection of H5 and N1 subtypes of AIV, including H5N1 subtypes and provide means for the diagnosis, surveillance and treatment of dangerous viral infections.Type: GrantFiled: September 11, 2012Date of Patent: November 5, 2013Assignee: Temasek Life Sciences Laboratory LimitedInventors: Hong Liang Qian, Fang He, Hwei-Sing Kwang
-
Publication number: 20130259871Abstract: Compositions and methods for the treatment or prevention of Dengue virus infection in a vertebrate subject are provided. In particular, human neutralizing monoclonal antibodies to Dengue virus isolated from EBV immortalized B cells derived from patients who have recovered from Dengue infection are disclosed. Methods are provided for administering such antibodies to a vertebrate subject in an amount effective to reduce, eliminate, or prevent relapse from infection.Type: ApplicationFiled: December 14, 2011Publication date: October 3, 2013Applicants: DSO NATIONAL LABORATORIES, NATIONAL UNIVERSITY OF SINGAPOREInventors: Paul Anthony Macary, Ee Ping Evelyn Teoh, Brendon John Hanson, En Wei Teo, Angeline Pei Chiew Lim, Mah Lee Mary Ng, Shee Mei Lok, Petra Eveliina Kukkaro
-
Publication number: 20130189279Abstract: The invention relates to binding molecules against Chikungunya virus, which are able of neutralizing Chikungunya virus infectivity, and which can be used with therapeutic, diagnosis or research purposes, as well as to a pharmaceutical composition comprising said binding molecules.Type: ApplicationFiled: April 7, 2011Publication date: July 25, 2013Applicant: Agency for Science, Technology and ResearchInventors: Lucile Warter, Jean-Pierre Abastado, Alessandra Nardin, Cheng-I Wang
-
Publication number: 20130171169Abstract: The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease.Type: ApplicationFiled: September 14, 2012Publication date: July 4, 2013Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
-
Publication number: 20130164734Abstract: The present invention provides monoclonal antibodies that are specific for the Dengue non-structural glycoprotein NS1 in monomeric and/or oligomeric (primarily dimeric) form, together with methods, including ELISA and lateral flow assays, that employ the disclosed antibodies for the early detection of Dengue virus infection. Diagnostic kits for the detection of Dengue infection are also provided, such kits including the disclosed monoclonal and/or polyclonal antibodies.Type: ApplicationFiled: September 27, 2012Publication date: June 27, 2013Applicant: INBIOS INTERNATIONAL, INC.Inventor: Inbios International, Inc.
-
Publication number: 20130149246Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: November 8, 2012Publication date: June 13, 2013Applicants: Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government of the United States of America, as represented by the Secretary, Department of HealtInventors: The Government of the United States of America,, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
-
Patent number: 8460670Abstract: The present invention relates to human antibodies, preferably to fully human antibodies, which are specifically binding to influenza M2e antigen. The invention further relates to individual light- and/or heavy chains of such antibodies, to nucleic acids encoding said antibodies or their light- and/or heavy chain, and to expression vectors for the expression of said anti-bodies. Furthermore, the invention relates to the use of said antibodies in the treatment and/or prevention of influenza A virus infection, preferably in humans.Type: GrantFiled: November 30, 2009Date of Patent: June 11, 2013Assignee: Intercell AGInventors: Martin F. Bachmann, Monika Bauer, Roger Beerli, Nicole Schmitz
-
Publication number: 20130084301Abstract: Compositions and methods are provided relating to human anti-HCV E2 monoclonal antibodies. The antibodies of the invention bind to a conserved region of HCV E2 protein, and neutralize HCV influenza virus across multiple HCV genotypes. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the human anti-HCV monoclonal antibodies; and cell lines that produce these monoclonal antibodies.Type: ApplicationFiled: August 30, 2012Publication date: April 4, 2013Inventors: Steven Foung, Zhen-Yong Keck
-
Publication number: 20130052163Abstract: The invention provides isolated fully human monoclonal anti-HRV antibodies, as well as method of making and using these antibodies. Anti-HRV antibodies of the invention prevent or treat subjects having HRV-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (COPD), sinusitis, bacterial superinfection, and cystic fibrosis.Type: ApplicationFiled: August 28, 2012Publication date: February 28, 2013Applicant: Theraclone Sciences, Inc.Inventor: Po-Ying Chan-Hui
-
Patent number: 8383121Abstract: Monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes or neuraminidase glycoprotein of N1 subtypes of avian influenza virus (AIV) are provided. The monoclonal antibodies and related binding proteins are useful for the detection of H5 and N1 subtypes of AIV, including H5N1 subtypes and provide means for the diagnosis, surveillance and treatment of dangerous viral infections.Type: GrantFiled: September 12, 2008Date of Patent: February 26, 2013Assignee: Temasek Life Sciences Laboratory LimitedInventors: Hong Liang Qian, Fang He, Hwei-Sing Kwang
-
Publication number: 20130028913Abstract: Described is an antibody or an antigen binding fragment thereof specifically binding to a full or empty H-1 parvovirus capsid. Such an antibody is useful for various diagnostic and therapeutic methods, e.g., for the detection/therapy of an H-1 parvovirus infection during pregnancy since parvovirus affects about 1 in 400 pregnancies and may cause fetal loss or fetal hydrops.Type: ApplicationFiled: December 1, 2010Publication date: January 31, 2013Inventors: Barbara Leuchs, Kathrin Kürschner, Andrea Kuck, Marcus Müller, Silvia Münstermann, Jean Rommelaere
-
Publication number: 20130029322Abstract: Monoclonal anti-HPV (human papillomavirus) E7 antibodies are capable of specifically recognizing an epitope of the C-terminal or the N-terminal region of a HPV E7 protein.Type: ApplicationFiled: February 16, 2011Publication date: January 31, 2013Applicants: AUSTRIA WIRTSCHAFTSSERVICE GESELLSCHAFT MBH, ÖSTERREICHISCHE AKADEMIE DER WISSENSCHAFTENInventors: Pidder Jansen-Dürr, Werner Zwerschke, Haymo Pircher, Daniela Ehehalt, Barbara Lener, Kerstin Dreier
-
Patent number: 8337853Abstract: The present invention relates to monoclonal antibodies that bind or neutralize dengue type 1, 2, 3, and/or 4 virus. The invention provides such antibodies, fragments of such antibodies retaining dengue virus-binding ability, fully human or humanized antibodies retaining dengue virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: GrantFiled: October 27, 2009Date of Patent: December 25, 2012Assignee: The United States of America as represented by the Secretary, Department of Health & Human ServicesInventors: Ching-Juh Lai, Robert H. Purcell
-
Publication number: 20120308580Abstract: There is provided at least one isolated TCR-like antibody or fragment thereof, wherein the antibody or fragment thereof is capable of specifically binding to at least one HBV derived peptide.Type: ApplicationFiled: November 19, 2010Publication date: December 6, 2012Applicants: NATIONAL UNIVERSITY OF SINGAPORE, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Antonio Bertoletti, Sastry Konduru Seetharama, Paul Anthony Macary, Soh Ha Chan, Chien Tei Too
-
Publication number: 20120294874Abstract: Methods are provided for producing T cell receptor (TCR) like antibodies that recognize peptides displayed in the context of HLA molecules. Antibodies produced by methods provided herein have the specificity of a TCR and can be used as therapeutic, diagnostic and research reagents. Also provided are TCR-like antibodies which recognize Epstein-Barr virus (EBV) peptides displayed in the context of HLA molecules and are useful for the detection and treatment of EBV and EBV-linked diseases.Type: ApplicationFiled: November 18, 2010Publication date: November 22, 2012Inventors: Paul Anthony Macary, Soh Ha Chan, Brendon John Hanson
-
Publication number: 20120264921Abstract: Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.Type: ApplicationFiled: July 8, 2010Publication date: October 18, 2012Applicant: GREEN CROSS CORPORATIONInventors: Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Kyung Hwan Ryoo, Dong Hyuck Seo, Jean Man Kim, Yong Nam Shin, Sunmi Koo, Jung-Ae Lim, Mijung Lee, Yeon Kyung Lee, Misun Seo
-
Publication number: 20120226023Abstract: Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.Type: ApplicationFiled: March 1, 2012Publication date: September 6, 2012Applicant: THE TRUSTEES OF PRINCETON UNIVERSITYInventors: Thomas Shenk, Dai Wang
-
Patent number: 8232048Abstract: Provided herein are a hybridoma cell line producing monoclonal antibody against foot-and-mouth disease virus (FMDV), the monoclonal antibody therefrom, reagent and kit for ELISA, and immunoassay method. The hybridoma cell line CmA40 as deposited under American Type Culture Collection patent deposit number PTA-11304 is produced by cell fusion of a parental cell and a myeloma cell line. The parental cell is a splenocyte isolated from the spleen of a mouse immunized by an antigen derived from a 3ABC non-structural protein (NSP) of FMDV. The antigen used here is expressed by a prokaryotic cell. The monoclonal antibody produced by the hybridoma cell line CmA40 as deposited under American Type Culture Collection patent deposit number PTA-11304 can specifically recognize a 3ABC polypeptide and does not cross-react with an antiserum of swine vesicular disease virus.Type: GrantFiled: July 13, 2010Date of Patent: July 31, 2012Assignee: Animal Health Research Institute, Council of Agriculture, Executive YuanInventors: Tsu-Han Chen, Fan Lee, Chu-Hsiang Pan, Ming-Hwa Jong
-
Publication number: 20120164153Abstract: We disclose Ebola Sudan Boniface virus GP Monoclonal antibodies, epitopes recognized by these monoclonal antibodies, and the sequences of the variable regions of some of these antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutic treatment of Ebola Sudan Boniface virus infections in vitro and in vivo.Type: ApplicationFiled: September 1, 2010Publication date: June 28, 2012Applicant: The Government of the United States, as Represented by the Secretary of the ArmyInventors: John M. Dye, Ana I. Kuehne, Shawn B. Guest
-
Patent number: 8206951Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.Type: GrantFiled: July 15, 2011Date of Patent: June 26, 2012Assignee: MedImmune, LLCInventors: Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
-
Patent number: 8187874Abstract: The present invention relates to drug discovery methods, particularly antiviral drug discovery methods.Type: GrantFiled: October 27, 2004Date of Patent: May 29, 2012Assignee: Vertex Pharmaceuticals IncorporatedInventors: Robert B. Perni, Cynthia Gates, John Thomson
-
Patent number: 8153129Abstract: The present invention provides novel antibody sequences that bind human cytomegalovirus (hCMV) and neutralize hCMV infection. The novel sequences can be used for the medical management of hCMV infections, in particular for preparing pharmaceutical compositions to be used in the prophylactic or therapeutic treatment of hCMV infections.Type: GrantFiled: December 17, 2007Date of Patent: April 10, 2012Assignee: Ribovax Biotechnologies S.A.Inventors: Ada Funaro, Giorgio Gribaudo, Santo Landolfo
-
Publication number: 20120082666Abstract: The invention provides compositions comprising anti-gH antibodies and anti-Complex I antibodies as well as methods of using the same.Type: ApplicationFiled: September 29, 2011Publication date: April 5, 2012Inventors: Xiaocheng Chen, Mark Dennis, Becket Feierbach, Ashley Fouts, Isidro Hotzel, Bing Li
-
Publication number: 20120076758Abstract: The present invention relates to compositions comprising antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV), and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV), infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions.Type: ApplicationFiled: April 29, 2011Publication date: March 29, 2012Applicant: WASHINGTON UNIVERSITYInventors: MICHAEL DIAMOND, THEODORE OLIPHANT, CHRISTOPHER MICHAEL DOANE
-
Publication number: 20120070446Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.Type: ApplicationFiled: October 5, 2010Publication date: March 22, 2012Applicant: AIMM THERAPEUTICS B.V.Inventors: TIM BEAUMONT, ADRIANUS Q. BAKKER, ETSUKO YASUDA
-
Publication number: 20120070447Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: ApplicationFiled: October 18, 2010Publication date: March 22, 2012Applicant: MEDIMMUNE, LLCInventors: JAMES F. YOUNG, SCOTT KOENIG, LESLIE S. JOHNSON, WILLIAM D. HUSE, JEFFREY D. WATKINS, HERREN WU
-
Publication number: 20120064000Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: August 1, 2011Publication date: March 15, 2012Applicants: Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government of the United Sates of America, as represented by the Secretary, Department of HealthInventors: Dimiter S. Dimitrov, Zhongyu Zhu, Christopher C. Broder
-
Patent number: 8124091Abstract: Human, humanized and chimeric monoclonal antibodies that bind to influenza M2 protein. A human monoclonal antibody that binds to influenza M2 protein having different amino acid sequences. The antibodies are useful for, among other things, treatment, diagnostics, purifying and isolating M2 or influenza virus, and identifying the presence of M2 or influenza virus in a sample or a subject.Type: GrantFiled: December 5, 2005Date of Patent: February 28, 2012Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Shinichiro Kato, Rongfang Wang
-
Publication number: 20120039846Abstract: The present invention provides identification and characterization of conformational epitopes of the envelope protein E2 of the Hepatitis C virus (HCV). The present invention provides a panel of human monoclonal antibodies that recognize conformational epitopes of E2. The antibodies are derived from patients infected with HCV. The present invention provides methods for utilizing HCV antibodies as therapeutic, diagnostic, and/or prophylactic agents. The present invention provides mimotopes with conformational epitopes intact and methods of using mimotopes. The present invention provides methods of stratifying patients based on their response to HCV. The present invention provides pharmaceutical compositions for prevention and treatment of HCV comprising one or more HCV antibodies.Type: ApplicationFiled: October 5, 2008Publication date: February 16, 2012Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Steven Foung, Zhen-yong Keck
-
Patent number: 8114586Abstract: Conformational epitopes of the envelope proteins E1 and E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conserved conformational and linear epitopes of the HCV protein E1 or E2 have been determined to be important in the immune response of humans to HCV and may be particularly important in neutralizing the virus. Based on the identification of these conformational epitopes, vaccines containing peptides and mimotopes with these conformational epitopes intact may be prepared and administered to patients to prevent and/or treat HCV infection. The identification of four distinct groups of monoclonal antibodies with each directed to a particular epitope of E1 or E2 may be used to stratify patients based on their response to HCV and may be used to determine a proper treatment regimen.Type: GrantFiled: December 11, 2008Date of Patent: February 14, 2012Assignee: Board of Trustees of Leland Stanford Junior UniversityInventors: Steven K. H. Foung, Kenneth G. Hadlock, Zhen-yong Keck
-
Publication number: 20120020980Abstract: Antibodies to human Cytomegalovirus (CMV) gB protein have been isolated from human B cells. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.Type: ApplicationFiled: June 16, 2011Publication date: January 26, 2012Applicant: TRELLIS BIOSCIENCE, INC.Inventors: LAWRENCE M. KAUVAR, STOTE ELLSWORTH, WILLIAM USINGER, KRISTA MAUREEN MCCUTCHEON, YING-PING JIANG, FEN ZHANG, BO CHEN, GIZETTE SPERINDE, MINHA PARK, ORIT FOORD
-
Publication number: 20120020957Abstract: The invention relates to antibodies and antigen binding fragments thereof and to cocktails of antibodies and antigen binding fragments that neutralize dengue virus infection without contributing to antibody-dependent enhancement of dengue virus infection. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antigen binding fragments. In addition, the invention relates to the use of the antibodies, antigen binding fragments, and epitopes in screening methods as well as in the diagnosis and therapy of dengue virus infection.Type: ApplicationFiled: October 13, 2009Publication date: January 26, 2012Applicant: Institute For Research in BiomedicineInventor: Antonio Lanzavecchia
-
Publication number: 20120009196Abstract: The present disclosure relates to anti-HCV core protein monoclonal antibodies, methods of making them, and their uses in the prevention, diagnosis, and/or treatment of disease including HCV infections.Type: ApplicationFiled: July 8, 2011Publication date: January 12, 2012Applicant: ABBOTT LABORATORIESInventors: A Scott Muerhoff, Susan E. Brophy, Bill J. Zeck
-
Publication number: 20120009623Abstract: The invention relates to a method for manufacturing recombinant anti-RSV antibodies and antibody compositions. The method comprises obtaining a collection of cells transfected with a collection of variant nucleic acid sequences, wherein each cell in the collection is transfected with and capable of expressing one distinct anti-RSV antibody. The cells are cultured under suitable conditions for expression of the anti-RSV antibody/antibodies. The nucleic acid sequence is introduced into the cells by transfection with expression vectors, which avoid site-specific integration. The present method is suitable for manufacturing recombinant mono- and polyclonal anti-RSV antibodies for therapeutic uses.Type: ApplicationFiled: September 23, 2011Publication date: January 12, 2012Inventors: Anne B. Tolstrup, Johan Lantto, Finn C. Wiberg, Lars S. Nielsen
-
Publication number: 20110318758Abstract: The present invention provides for methods of producing human monoclonal antibodies against a wide variety of antigens including bacterial and viral antigens, as well as tumor antigens, and various autoantigens. Also provided are the antibodies themselves, nucleic acids encoding such antibodies, cells producing such antibodies, and methods of using such antibodies for diagnostic assays and passive immunity against disease states such as infection and cancer.Type: ApplicationFiled: August 4, 2008Publication date: December 29, 2011Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENTInventors: Natalie Sutkowski, Semyon Rubinchik
-
Publication number: 20110311550Abstract: Provided are polypeptides, including antibodies and fragments thereof, useful for preventing or treating new or recurring infection of hepatitis C virus, as well as methods of preventing or treating new or recurring hepatitis C viral infection. Also provided are modified E1 and E2 polypeptides.Type: ApplicationFiled: October 23, 2009Publication date: December 22, 2011Applicant: The Scripps Research InstituteInventors: Mansun Law, Dennis R. Burton
-
Patent number: 8066998Abstract: Norovirus antigen peptides are described having an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-16, or fragments thereof. Such peptides can be used in the preparation of antiviral therapies such as vaccines, methods of preparing antibodies to the antigen peptides, methods of using the peptides or the corresponding antibodies for detection of norovirus, and compositions of the peptides, DNA and/or antibodies. A kit for the detection of norovirus is also provided.Type: GrantFiled: June 29, 2007Date of Patent: November 29, 2011Assignee: Kim Laboratories, Inc.Inventors: Jane Catherine Frye, Hoshin Park, Myung L. Kim
-
Publication number: 20110274702Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.Type: ApplicationFiled: July 18, 2011Publication date: November 10, 2011Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventor: Antonio Lanzavecchia
-
Publication number: 20110268740Abstract: The present invention relates to human antibodies, preferably to fully human antibodies, which are specifically binding to influenza M2e antigen. The invention further relates to individual light- and/or heavy chains of such antibodies, to nucleic acids encoding said antibodies or their light- and/or heavy chain, and to expression vectors for the expression of said anti-bodies. Furthermore, the invention relates to the use of said antibodies in the treatment and/or prevention of influenza A virus infection, preferably in humans.Type: ApplicationFiled: November 30, 2009Publication date: November 3, 2011Applicant: INTERCELL AGInventors: Martin F. Bachmann, Monika Bauer, Roger Beerli, Nicole Schmitz
-
Publication number: 20110268746Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: ApplicationFiled: July 15, 2009Publication date: November 3, 2011Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventors: Antonio Lanzavecchia, Annalisa MacAgno
-
Publication number: 20110263436Abstract: Recombinant antibodies, including chimeric antibodies, specific for hepatitis C (HCV) antigenic proteins are provided. The recombinant antibodies specifically bind to diagnostically relevant regions of HCV proteins and are thus suitable for use, for example, as diagnostic reagents for the detection of HCV, and/or as standardization reagents or positive control reagents in assays for the detection of HCV. The recombinant antibodies can also be used in the treatment or prevention of a HCV infection.Type: ApplicationFiled: November 22, 2010Publication date: October 27, 2011Applicant: ABBOTT LABORATORIESInventors: Bailin Tu, Joan D. Tyner, James W. Scheffel, Michael K. White, Jeffrey M. Werneke, Robert N. Ziemann, David J. Hawksworth, Mary S. Pinkus, Robin A. Gutierrez
-
Patent number: 7988972Abstract: The Epstein-Barr virus (EBV) specific polypeptides ETFTETWNRFITHTE (SEQ. ID NO: 1), GMLEASEGLDGWIHQ (SEQ. ID NO:2), HQQGGWSTLIEDNIP (SEQ. ID NO:3), and KQKHPKKVKQAFNPL (SEQ. ID NO:4) are among those disclosed. Also disclosed are the use of these polypeptides for the production of polypeptide-specific antibodies and the diagnosis and treatment of EBV-associated disease.Type: GrantFiled: December 14, 2007Date of Patent: August 2, 2011Assignee: Ortho-Clinical Diagnostics, Inc.Inventors: Richard S. Smith, Gary R. Pearson, D. Elliot Parks, Susan Pothen Varghese
-
Publication number: 20110171233Abstract: The present invention provides novel antibodies sequences that bind human cytomegalovirus (hCMV) and neutralize hCMV infection. The novel sequences can be used for the medical management of hCMV infections, in particular for preparing pharmaceutical compositions to be used in the prophylactic or therapeutic treatment of hCMV infections.Type: ApplicationFiled: July 31, 2008Publication date: July 14, 2011Applicant: RIBOVAX BIOTECHNOLOGIES S.A.Inventors: Ada Funaro, Giorgio Gribaudo, Santo Landolfo
-
Patent number: 7919314Abstract: Provided is a use of a recombinant chimaeric protein as an immunogen in a process for producing a monoclonal antibody, wherein the recombinant chimaeric protein is assembled into a virus-like particles, and includes a foreign protein or peptide or a fragment thereof.Type: GrantFiled: October 12, 2007Date of Patent: April 5, 2011Assignee: Biotechnologijos InstitutasInventors: Aurelija Zvirbliene, Alma Gedvilaite, Rainer Ulrich, Kestutis Sasnauskas
-
Publication number: 20110065089Abstract: The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.Type: ApplicationFiled: April 6, 2010Publication date: March 17, 2011Inventors: Sylvie Van Der Werf, Nicolas Escriou, Bernadette Crescenzo-Chaigne, Jean-Claude Manuguerra, Frederik Kunst, Benoît Callendret, Jean-Michel Betton, Valérie Lorin, Sylvie Gerbaud, Ana Maria Burguiere, Saliha Azebi, Pierre Charneau, Frédéric Tangy, Chantal Combredet, Jean-François Delagneau, Monique Martin
-
Publication number: 20110027294Abstract: Anti-Respiratory Syncytial Virus (RSV) monoclonal antibodies, RSV F protein antigens and their uses are disclosed.Type: ApplicationFiled: October 8, 2010Publication date: February 3, 2011Inventors: Alfred Delvecchio, Ping Tsui, Patrick Branigan, Leslee Conrad, Nicole Day, Changbao Liu, Raymond Sweet, Sheng-Jiun Wu, Jose Melero, Jinquan Luo, Gabriela Canziani, Mark Tornetta, Gopalan Raghunathan, Venkata Chalapathi Koka
-
Patent number: 7879326Abstract: A panel of IgG1 human monoclonal antibodies (HMAbs) identified by hemagglutination inhibition (HI) assay has been produced from peripheral B cells of an individual immunized with prototype H5N1 vaccine. Sequence analysis of antibody clones showed three clusters of different HMAbs as represented by HMAbs designated as BF1-1, BF1-19 and BF1-10. BF1-1 and BF1-10 have distinct CDR 1, 2 and 3 regions of both heavy and light chains. BF1-19 has the same heavy chain as BF1-1 but the light chain of BF1-10. Antibody binding affinity, KD, studies showed all three HMAbs ranging from at least about 10?8 to at least about 10?9. In vivo protection studies showed that these antibodies afforded significant protection against infection. These findings demonstrate that the antibodies of the invention are cross-neutralizing and therapeutic.Type: GrantFiled: June 16, 2008Date of Patent: February 1, 2011Assignees: The Board of Trustees of the Leland Stanford Junior University, St. Jude Children's Research HospitalInventors: Steven Foung, Zhen-Yong Keck, Richard Webby
-
Publication number: 20110014639Abstract: Provided herein are a hybridoma cell line producing monoclonal antibody against foot-and-mouth disease virus (FMDV), the monoclonal antibody therefrom, reagent and kit for ELISA, and immunoassay method. The hybridoma cell line is produced by cell fusion of a parental cell and a myeloma cell line and has the same characteristics as the cell line whose strain designation is CmA40 and deposition number is ATCC (To be Provided). The parental cell is a splenocyte isolated from the spleen of a mouse immunized by an antigen derived from a 3ABC non-structural protein (NSP) of FMDV. The antigen used here is expressed by a prokaryotic cell. The monoclonal antibody produced by the hybridoma cell line can specifically recognize a 3ABC polypeptide and does not cross-react with an antiserum of swine vesicular disease virus.Type: ApplicationFiled: July 13, 2010Publication date: January 20, 2011Inventors: Tsu-Han Chen, Fan Lee, Chu-Hsiang Pan, Ming-Hwa Jong
-
Publication number: 20100279400Abstract: The present invention provides a rapid and sensitive method for the detection of a West Nile virus (WNV), Japanese encephalitis virus (JEV), St. Louis encephalitis virus (SLEV) and Dengue virus (DENV) and antibodies directed against thereof involving contacting a biological specimen suspected of being infected with WNV, JE, SLE or DEN with a substantially purified and isolated WNV E glycoprotein or subfragment thereof having a native conformation wherein the E glycoprotein or subfragment thereof has a reactivity with antibodies against WNV and a cross-reactivity with antibodies against JEV, SLEV and DENV. The instant invention further provides a rapid, sensitive, and consistent method for the specific detection of WNV by employing diagnostic assays having the antigen NS5 which is specifically reactive with anti-WNV antibodies but not cross-reactive with antibodies against other flaviviruses such as JEV, SLEV, or DENV.Type: ApplicationFiled: April 1, 2008Publication date: November 4, 2010Inventors: Susan J. Wong, Pei-Yong Shi
-
Patent number: 7811568Abstract: Humanized monoclonal antibodies against the vaccinia virus B5R surface antigen. The antibodies are effective in treating smallpox infection. Also disclosed are nucleic acids that encode the heavy and light chains of such antibodies and cells that express them.Type: GrantFiled: August 22, 2007Date of Patent: October 12, 2010Assignee: Quercegen PharmaInventors: Jean-Pierre Kinet, Marie-Helene Jouvin